April 5, 2016
Off
New U.S. inversion rules threaten Pfizer-Allergan deal
By Dino MustafićThe U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.